Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk
Posted on December 17, 2018 in Forbion, Forbion highlight, Highlights
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia.
Naarden, The Netherlands, and Munich, Germany – 17 December 2018 – Forbion today announces that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.
